Abstract
Product description
The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists &
Antagonists as of September 2007 provides a competitor analysis in the
development pipeline of novel small molecules, proteins, DNA, RNA and vaccines
targeting the toll-like receptors TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 for
treatment of cancer, infectious diseases, sepsis and allergy. The analysis
details molecules targeting one or more of the toll-like receptors and
includes agonists, antagonists as well as vaccines and vaccine adjuvants. TLR
Agonists as well as TLR Antagonists are presented sorted by receptor subtype
and by therapeutic area. A list of TLR Adjuvants used in marketed vaccines and
in vaccines under development is provided. TLR-adjuvanted vaccines are
compiled sorted by TLR receptor subtype and by therapeutic area as
prophylactic and therapeutic vaccines. The corporate R&D portfolios (more than
one project) for TLR Agonists, Antagonists, Adjuvants and TLR-Adjuvanted
Vaccines contained in this Competitor Analysis.
The report includes a compilation of current active projects in research and
development of TLR agonists, antagonists, adjuvants and vaccines.
Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Therapeutic Area,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
| 
View Cart
